高龄白内障患者术毕前房注射地塞米松临床观察

目的 探讨高龄白内障患者术毕前房注射地塞米松注射液的临床疗效和安全性.方法 于2011年1月至2013年1月在眼科就诊的100例高龄(＞80岁)的单纯性白内障患者,均排除糖尿病及其他眼部疾病.将所有患者分为实验组和对照组,每组均为50例(50只眼),均由相同的专业技术医师行小切口白内障囊外摘除+人工晶状体植入术.实验组术毕于前房内注入地塞米松注射液0.5 mg,对照组不干预.术后裂隙灯下观察角膜水肿、前房渗出、房水闪辉情况、对比眼压等.结果 经两独立样本的秩和检验分析实验组角膜水肿、前房渗出、房水闪辉较对照明显减轻,比较差异有统计学意义(P＜0.05);而通过HotellingT2检验实验组与对照组眼压差异无统计学意义(P＞0.05).结论 单纯高龄白内障患者术毕前房注射地塞米松注射液,可有效地减轻术后角膜水肿及前房炎症反应,对眼压无明显影响,无并发症发生.该方法安全、有效地提高了手术效果.     

普南扑灵滴眼剂合并地塞米松对白内障术后炎症的疗效

目的评估普南扑灵滴眼剂在减轻白内障术后炎症反应中的疗效及其副作用。方法100例(122眼)白内障患者采用囊外摘除术加人工晶状体植入,术后随机分为治疗组和对照组,治疗组50例(58眼),选用0.1%普南扑灵滴眼剂点眼加0.025%地塞米松滴眼剂点眼,对照组50例(64眼),选用0.025%地塞米松滴眼剂点眼。观察指标为眼部畏光、异物感、流泪、疼痛等症状及充血、前房闪辉、角膜炎症、前房浮游体、KP及虹膜后黏连等体征,以各项指标的综合评分评价其疗效。结果治疗组在术后第3天、第7天、第14天综合评分优于对照组,差异有显著性(P<0.05);第21天差异无显著性(P>0.05)。结论普南扑灵联合地塞米松滴眼剂点眼能显著地减轻白内障术后的炎症反应。     

曲安奈德在外伤性白内障手术中的应用

目的 观察曲安奈德在外伤性白内障手术中的作用.方法 对32例32眼外伤性白内障行白内障摘出术.晶状体后囊完整的10例10眼行常规小切口白内障囊外摘出术,人工晶状体植入囊袋后向前房内注入曲安奈德;伴有后囊破裂玻璃体脱入前房的22例22眼行白内障摘出联合前段玻璃体切割术,术中前房内注入曲安奈德,完全清除前房内的玻璃体皮质.术后观察角膜情况、前房内炎症反应、眼压变化、黄斑水肿情况、视力预后等.结果 32例患者术后仅有2例因角膜破口较大且不规则而发生角膜水肿,3例患者发生后囊混浊.所有患者前房清亮,无炎症反应,无不可耐受的眼压升高,检眼镜下未见明显的黄斑水肿.结论 外伤性白内障术中使用曲安奈德,可以提高手术的可视性和安全性,抑制术后炎症反应,减少近期及远期并发症,视力预后较好.     

地塞米松缓释微粒控制糖尿病白内障术后炎症的临床观察

目的　观察地塞米松缓释微粒植入前房内对控制糖尿病性年龄相关性白内障人工晶体植入术后炎症的作用。方法　对 60例糖尿病性年龄相关性白内障患者行小切口非超乳人工晶体植入术 ,其中 3 0例植入地塞米松缓释微粒 ,另 3 0例为对照组。观察术后 1天、 3天、 7天房水混浊及纤维蛋白渗出及膜形成情况。结果　植入地塞米松缓释微粒组明显轻于对照组 ,两组差异具有显著性(P <0 0 5 )。结论　地塞米松缓释微粒植入前房控制术后炎症安全、有效、可靠。     

地塞米松缓释剂在葡萄膜炎并发白内障人工晶体植入术中的应用

目的观察地塞米松缓释剂前房内植入对葡萄膜炎并发白内障人工晶体植入术后炎症反应,后囊混浊的预防和治疗效果。方法将近4年来我院就诊的46例（46眼）葡萄膜炎并发白内障患者随机分为两组,一组（22例）行超声乳化术＋人工晶体植入术后前房内植入地塞米松缓释剂,另一组（24例）为对照组,只做超声乳化术＋人工晶体植入,观察两组术后视力,眼压,前房炎症及后发障的发生率。结果术后视力：植入组≥1.0者9例,0.5～0.8者8例,0.1～0.4者5例,〈0.1者2例。术后高眼压、前房炎症和后囊混浊发生情况：植入组明显低于对照组,差异有统计学意义（P〈0.05）。结论前房内植入地塞米松缓释剂可有效地减轻葡萄膜炎并发白内障人工晶体植入术后炎症反应,预防后发障的发生,是一种安全有效的给药途径。     

地塞米松缓释剂在并发性白内障术中前房植入

目的　评价地塞米松缓释剂前房内植入对前葡萄膜炎并发性白内障术后炎症反应和后囊浑浊的预防效果。方法　 68例 ( 68眼 )前葡萄膜炎并发性白内障行白内障摘出人工晶状体植入术者随机分为两组 ,植入组 3 6例 ,术中前房内植入地塞米松缓释剂 ;对照组 3 2例 ,术中未植入该缓释剂。观察并比较两组术后炎症反应情况及后发障发生率。结果　术后前房炎症和后囊浑浊 ,植入组明显低于对照组 ,差异有显著性意义 (P <0 .0 5 )。结论　前房内植入地塞米松缓释剂可减轻葡萄膜炎并发性白内障人工晶状体植入术后炎症反应 ,减少后发性白内障。是一种安全有效的给药途径。     

青光眼滤过术后白内障患者行超声乳化联合人工晶状体植入术毕前房注射地塞米松的临床疗效

目的　评价青光眼滤过术后白内障患者行超声乳化联合人工晶状体植入术毕前房注射地塞米松的临床疗效。方法　选取青光眼滤过术后白内障患者９８例（１２０眼）,由同一医师进行白内障超声乳化联合人工晶状体植入术。所有患者随机分组,对照组４８例（６０眼）术毕给予地塞米松注射液０．５ｍＬ（２．５ｍｇ）球结膜下注射;试验组５０例（６０眼）术毕前房内注射０．１ｍＬ（０．５ｍｇ）地塞米松注射液。观察并比较两组患者手术后最佳矫正视力、前房反应、眼压、角膜内皮细胞计数、六角形细胞比率的差异。结果　青光眼滤过术后白内障超声乳化联合人工晶状体植入术后１ｄ、３ｄ最佳矫正视力试验组比对照组效果更好,２组比较差异有统计学意义（Ｐ＜０．０５）,术后１周最佳矫正视力两组间差异无统计学意义（Ｐ＞０．０５）;对照组与试验组术前,术后１ｄ、３ｄ、１周、１个月、３个月眼压组间比较差异均无统计学意义（均为Ｐ＞０．０５）;对照组与试验组术后１ｄ、３ｄ、１周前房炎症反应组间差异有统计学意义（均为Ｐ＜０．０５）,试验组眼前房炎症反应较轻;对照组与试验组术后３ｄ、１周、１个月角膜内皮细胞密度、六角形细胞百分比及变异系数组间比较差异均有统计学意义（均为Ｐ＜０．０５）,对照组较试验组术后细胞密度明显降低,六角形细胞百分比下降,变异系数增高。结论　青光眼滤过术后白内障超声乳化联合人工晶状体植入术毕前房注射地塞米松注射液是安全有效的,对术后短期内获得最佳矫正视力、减轻前房反应、减少角膜内皮细胞的丢失具有积极的临床意义。     

曲安奈德前房注射在前葡萄膜炎并发白内障手术中的疗效观察

目的观察曲安奈德(TA)前房注射在前葡萄膜炎并发白内障手术中的有效性及安全性。方法葡萄膜炎并发白内障患者34例(38只眼),均由同一医师进行手术。所有患者随机分为对照组(19只眼)和实验组(19只眼)。实验组所有患者均行透明角膜切口白内障超声乳化吸除联合人工晶状体植入术,术毕前房内注入TA1mg;对照组术式同实验组,术毕未行TA注入。观察术后7 d患者视力情况;术后1、3、7 d患者前房炎症反应情况;术后1、7、14 d及1个月时眼压情况;术后1、4及8周角膜内皮计数。结果术后1、3、7 d实验组前房炎症反应明显低于对照组,差异有统计学意义,术后各时间点两组患者眼压及角膜内皮计数均在正常范围,差异无统计学意义。结论 TA前房注射在前葡萄膜炎并发白内障手术中可有效控制前房炎症反应,无明显不良反应。     

儿童白内障术中植入地塞米松缓释胶囊的疗效观察

目的　观察儿童白内障术中前房植入地塞米松缓释胶囊思诺迪清的疗效。方法　 1 0例 1 5眼儿童白内障术中前房植入思诺迪清 ,观察术后视力及并发症。结果　 3例能合作者术后矫正视力0 4～ 0 6;术后除 1例人工晶体表面少量渗出外 ,其余前房反应极轻。结论　儿童白内障术中前房植入思诺迪清能明显地减轻前房炎症反应     

初学者行扭动超声乳化白内障摘除术的临床观察

目的:探讨白内障手术初学者施行扭动超声乳化技术的安全性及稳定性。方法:回顾2012-02/2013-03白内障手术初学者首次行超声乳化手术200眼的临床资料,分析手术并发症,评估术后效果。结果:术中无一眼出现前房塌陷,在最后一块核吸除瞬间后囊有轻微浪涌现象。术中出现8眼破囊,5眼行前段玻璃体切割后将人工晶状体植入睫状沟,其余3眼破口较小无玻璃体溢出,将人工晶状体植入囊袋内。1眼撕囊时裂到边缘转上级医生改行白内障囊外摘除术(ECCE)。1眼术中发现悬韧带松弛,由上级医生植入囊袋张力环后植入人工晶状体。7眼巩膜隧道切口过短,需行切口缝合。术后1wk裸眼视力:术后视力<0.05者2眼(1%),0.05～者31眼(15.5%),≥0.3者64眼(32%),≥0.5者103眼(51.5%)。术后无3级及以上角膜水肿。术后高眼压经过前房放液或局部用药后均可恢复正常。结论:白内障超声乳化手术初学者使用扭动超声乳化技术安全、有效。     

Randomized clinical trial of surodex steroid drug delivery system for cataract surgery: Anterior versus posterior placement of two surodex in the eye

OBJECTIVE: To evaluate safety and antiinflammatory efficacy of placing two Surodex (Oculex Pharmaceuticals, Inc., Sunnyvale, CA) in the eye after cataract surgery in comparison with steroid eyedrops and to compare anterior versus posterior chamber placement. DESIGN: Randomized, masked, controlled trial. PARTICIPANTS: One hundred four eyes of 104 Asian patients undergoing extracapsular cataract extraction with intraocular lens implantation were examined. Of these, 33 eyes of 33 patients served as control eyes (group A). INTERVENTION: Two Surodex pellets were inserted in the anterior chamber (AC) of 35 eyes (group B), and two Surodex pellets were inserted in the ciliary sulcus of 36 eyes (group C) at the conclusion of surgery. Control eyes received neither Surodex nor a placebo implant, but were prescribed conventional 0.1% dexamethasone eyedrops four times daily for 4 weeks. MAIN OUTCOME MEASURES: Anterior chamber flare and cells were graded clinically at the slit lamp. Anterior chamber flare was assessed objectively with the Kowa FC500 Laser Flare Meter (Kowa Co. Ltd, Tokyo, Japan). Intraocular pressure and corneal endothelial specular microscopy with morphometric cell analysis were performed for up to 1 year after surgery. RESULTS: Lower flare meter readings occurred in both Surodex groups at all postoperative visits, as compared with the dexamethasone eyedrop group, with statistical significance at days 4 (P = 0.001), 8 (P = 0.001), and 15 (P = 0.02). No difference in flare occurred between AC and ciliary sulcus placement. Clinical slit-lamp assessment of anterior chamber flare and cells showed no difference between Surodex-treated eyes and dexamethasone-treated eyes. Nine of 33 eyes (27.3%) in group A required steroid augmentation, as opposed to 4 of 71 eyes (5.6%) in groups B and C. Inflammatory symptoms were reduced in the Surodex-treated eyes, with statistical significance for ocular discomfort (P = 0.001), photophobia (P = 0.04), and lacrimation (P = 0.01). No complications occurred with Surodex-treated eyes, and no significant difference in endothelial cell loss was noted between Surodex-treated eyes and dexamethasone-treated eyes up to 1 year after surgery. CONCLUSIONS: Intraocular placement of two Surodex is a safe and effective treatment method to reduce intraocular inflammation after cataract surgery and clearly is superior to eyedrops in reducing inflammatory symptoms and aqueous flare as measured with the laser flare meter. No difference in efficacy between AC placement and ciliary sulcus placement of Surodex was detected in this study.     

Randomized clinical trial of a new dexamethasone delivery system (surodex) for treatment of post-cataract surgery inflammation

ObjectiveTo evaluate the safety of Surodex Drug Delivery System (Oculex Pharmaceuticals, Inc., Sunnyvale, CA) containing dexamethasone 60 μg, for use in cataract surgery, and to compare its anti-inflammatory efficacy with conventional dexamethasone 0.1% eyedrops.DesignRandomized, masked, and partially controlled trial.ParticipantsSixty eyes of 60 Asian patients undergoing extracapsular cataract extraction with intraocular lens implantation were examined. Of these, 28 eyes of 28 patients served as control eyes. Patients were stratified for age and presence of diabetes mellitus.InterventionSurodex was inserted in the anterior chamber of 32 eyes at the conclusion of surgery. These eyes received placebo eyedrops four times a day after surgery for 4 weeks. Control eyes received neither Surodex nor a placebo implant but were prescribed conventional 0.1% dexamethasone eyedrops four times a day for 4 weeks.Main outcome measuresAnterior chamber cells and flare were clinically graded at the slit lamp. Anterior chamber flare was objectively assessed with the Kowa FM500 Laser Flare Meter (Kowa Co. Ltd, Tokyo, Japan) for up to 3 months after surgery. Intraocular pressure and corneal endothelial specular microscopy with morphometric cell analysis were performed for up to 1 year after surgery.ResultsClinical slit-lamp assessment of anterior chamber flare and cells showed no difference between Surodex-treated eyes and dexamethasone eyedrop-treated eyes. Flare meter readings showed lower flare levels in the Surodex group at all postoperative visits compared with the dexamethasone eyedrop group. Flare reduction in the Surodex group reached statistical significance at days 4, 8, 15, and 30 after surgery. At 3 months, flare was reduced to preoperative levels in the Surodex group but was still raised in the dexamethasone eyedrop group. Five eyes in the dexamethasone eyedrop group required augmentation of steroids and were deemed therapeutic failures as opposed to one eye in the Surodex group. One patient in the dexamethasone eyedrop group developed postoperative open-angle glaucoma with profound visual field loss and optic disc cupping, resulting in hand movements vision. No significant difference in endothelial cell loss was noted between Surodex-inserted eyes and dexamethasone eyedrop-treated eyes for up to 1 year after surgery.ConclusionsIntraocular placement of a single Surodex is a safe and effective treatment method to reduce intraocular inflammation after cataract surgery. There was no statistical difference in efficacy between Surodex and 0.1% dexamethasone eyedrops in reducing intraocular inflammation, as measured by clinical methods, while Surodex was clearly superior to eyedrops in reducing aqueous flare as objectively assessed with the laser flare meter.     

Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification

PURPOSE: To compare the safety and efficacy of the Surodex dexamethasone anterior segment drug delivery system (Oculex Pharmaceuticals, Inc.) and dexamethasone 0.1% eyedrops (Maxidex) in patients with inflammation after cataract surgery. SETTING: Cataract Service, Department of Ophthalmology, Lothian University Hospitals, Edinburgh, United Kingdom. METHODS: This comparative single-masked parallel-group study comprised 1 eye of 19 patients having phacoemulsification cataract extraction and posterior chamber intraocular lens implantation. The Surodex group had the dexamethasone drug delivery system inserted into the anterior chamber (AC) angle during surgery and was treated with saline eyedrops (Isopto Plain) for 4 weeks. The control group had no drug delivery system or a placebo inserted at surgery and were treated with dexamethasone 0.1% eyedrops for 4 weeks. A Kowa FM-500 laser flare meter was used to objectively measure AC flare, the main outcome measure. Slitlamp biomicroscopy to grade AC flare and cells, intraocular pressure measurement, and corneal endothelial specular microscopy, performed up to 60 days after surgery, were the secondary outcome measures. The Surodex group had safety follow-ups after completion of the initial study period. RESULTS: Both groups had a steady increase in laser flare meter readings postoperatively. The readings peaked at 3 days in the control group and at 7 days in the Surodex group. This was followed by a gradual decline toward baseline values up to 28 days, after which the values remained at a similar level to 60 days in both groups. There were no significant differences in flare meter readings between the groups throughout the study. There were also no significant between-group differences in subjective assessment of intraocular inflammation and in impact on corneal endothelial cell count (P =.67). Surodex remnants persisted up to a mean of 22.0 months +/- 2.5 (SD) postoperatively in 6 eyes (54%). Neither group had a severe adverse event. CONCLUSION: Surodex appeared to be as effective as dexamethasone 0.1% eyedrops in controlling intraocular inflammation after cataract surgery by phacoemulsification, and both methods had a similar safety profile.     

白内障后囊破裂人工晶状体睫状沟固定与植入前房疗效比较

目的:比较睫状沟缝线固定人工晶状体术和前房人工晶状体植入术治疗白内障后囊破裂的疗效。方法:回顾性分析采用睫状沟缝线固定人工晶状体术、前房人工晶状体植入术治疗白内障后囊破裂45例45眼,比较两组手术的疗效。结果:睫状沟缝线固定人工晶状体术组和前房人工晶状体植入术组均能有效治疗白内障后囊破裂。但后者术后有2例6mo后出现虹膜睫状体炎及眼压升高,其余视力均改善。前者视力均改善,未见有明显的并发症。结论:睫状沟缝线固定人工晶状体术和前房人工晶状体植入术均能有效治疗白内障后囊破裂,改善视力,但前者更接近于生理位置,术后并发症更少。     

后囊破裂型外伤性白内障人工晶状体二期植入

目的探讨人工晶状体二期睫状沟植入在眼球穿孔伤所致后囊破裂型外伤性白内障手术中的应用。方法我院2011年1月至2013年1月收治眼球穿孔伤所致后囊破裂型外伤性白内障82例（82眼）,在一期眼球清创缝合白内障摘出联合前段玻璃体切除手术时尽量保留残余囊袋。3～6个月后行二期人工晶状体植入术。根据囊袋残留情况分为两组：A组：残留囊袋足够支撑后房型人工晶状体者（48例）,进行后房型人工晶状体睫状沟植入。B组：囊袋无残留或残留囊袋无法支撑后房型人工晶状体者（34例）,进行缝线固定晶状体襻于巩膜壁的后房型人工晶状体睫状沟植入。结果两组患者术后视力均有提高。B组BCVA明显低于A组。A组2例（4．17％）人工晶状体光学中心轻度偏移,4例（8．33％）体部轻度倾斜;B组6例（17．65％）人工晶状体光学中心轻度偏移,6例（17．65％）体部倾斜,其中3例（8．82％）眼球转动时有不适感。结论对于眼球穿孔伤所致后囊破裂型外伤性白内障,于一期行眼球清创缝合、白内障摘出联合前段玻璃体切除手术时尽量保留残余囊袋组织,可为二期植入人工晶状体创造良好条件。二期手术时选择后房型人工晶状体睫状沟植入术,符合人体解剖结构,稳定性好。     

曲安奈德前房注射在青光眼联合白内障手术中的临床疗效观察

目的观察曲安奈德（TA）前房注射对急性闭角型青光眼患者青光眼联合白内障手术后眼内反应的影响,探讨TA在青光眼联合白内障摘出手术中的应用价值。方法36例（36只眼）急性闭角型青光眼患者由同一医师完成青光眼联合白内障手术。对照组18例（18只眼）行青光眼联合白内障手术,实验组18例（18只眼）行青光眼联合白内障手术,术毕前房内注射1mg TA。观察术后第1、3、7天视力、前房炎症反应情况和术后1、3、7天、2周、1个月眼压以及术前、术后1周、2周、1个月角膜内皮计数。结果术后第1、3、7天前房反应实验组明显低于对照组,差异均有统计学意义。术后第1、3、7天、2周、1个2组相应时间点眼压比较差异均无统计意义。术前及术后1周、2周、1个月实验组及对照组角膜内皮计数差异无统计意义。术后早期2组均有轻度角膜水肿,7d左右恢复正常。结论TA可以抑制急性闭角型青光眼患者青光眼联合白内障手术后早期眼内炎症反应,缩短术后恢复时间,无明显不良反应。     

Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery

Purpose: To compare the efficacy and safety of rimexolone 1% and prednisolone acetate 1% ophthalmic suspensions in controlling intraocular inflammation in the early period after cataract surgery. Methods: Eighty patients undergoing cataract extraction with intraocular lens implantation, either planned extra capsular cataract extraction (PECCE) or phacoemulsification surgery, were evaluated in a prospective, randomized, observer-masked, clinical trial in which efficacy in controlling early postoperative inflammation and safety of prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes) was compared with that of rimexolone 1% one eye drop every 4 h (n = 44 eyes) in an eighteen day course. Efficacy was assessed from changes of the anterior chamber cell count, flare, conjunctival hyperemia, and ciliary congestion by means of slit lamp biomicroscopy on days 1, 3, 8, 15, and 18. Intraocular pressure (IOP) and possible side effects were also recorded on each visit. Results: Anterior chamber cell count and flare showed no difference in the two groups at any visits. The rimexolone group was associated with significantly higher score for conjunctival hyperemia on days one and three (P < 0.05) and the prednisolone acetate group was associated with a significantly higher score for corneal edema on day 8 (P < 0,05). However, there were no between group differences in IOP. Conclusions: Rimexolone 1% ophthalmic suspension was as effective and safe as prednisolone acetate 1% ophthalmic suspension in controlling inflammation in the early period after cataract surgery.     

Pentacam眼前节分析系统在评价氯替泼诺控制白内障术后炎症疗效中的应用

目的 观察氯替泼诺(5 g· L-1 Lotemax混悬滴眼液,露达舒)控制白内障超声乳化联合人工晶状体植入术后炎症的有效性和安全性.方法 选择Ⅲ级核以上的老年性白内障患者60例,随机分为2组.患者接受白内障超声乳化吸出联合人工晶状体植入术后,分别给予5g·L“露达舒滴眼液+托百士滴眼液(露达舒组)或者典必殊滴眼液(典必殊组)治疗.术后ld、7d、30 d观察角膜水肿、前房闪辉、角膜容积、前房容积、角膜切口厚度.术前,术后7d、30 d观察眼压情况.应用Pentacam眼前节分析系统定量分析评价露达舒控制白内障术后炎症的疗效.结果 角膜水肿、前房闪辉、角膜容积、前房容积、角膜切口厚度:术后ld、30 d两组比较差异均无统计学意义(均为P＞0.05).术后7d,典必殊组前房闪辉和角膜容积均明显小于露达舒组(P=0.029、0.019),角膜水肿、前房容积、角膜切口厚度比较差异均无统计学意义(P=0.119、0.138、0.101).术前,术后7d、30 d两组间眼压差异均无统计学意义(均为P＞0.05).结论 氯替泼诺可有效控制白内障超声乳化吸出联合人工晶状体植入术后的前房炎症.     

曲安奈德在糖尿病性白内障手术中的应用研究

目的观察糖尿病性白内障术中前房内注射曲安奈德的效果和安全性。方法47例（47眼）糖尿病性白内障随机分为两组：试验组（23例）术中前房内注入曲安奈德2mg;对照组（24例）术中前房内注入生理盐水。观察并比较两组术后眼压变化、角膜内皮细胞密度、前房纤维蛋白渗出情况及后发障的发生率等。结果术后前房纤维蛋白渗出和后发障,试验组明显低于对照组,差异有统计学意义（P〈0．05）;而术后眼压变化、角膜内皮细胞密度两组比较差异无统计学意义（P〉0．05）。结论糖尿病性白内障术中前房内注入曲安奈德,可减轻术后炎症反应,减少近期及远期并发症。     

曲安奈德前房内注射在外伤性白内障术中的应用

目的:探讨前房内注射曲安奈德(triamcinolone acetonide,TA)在外伤性白内障术中的安全性和有效性.方法:收集2013-01/2016-05的31例31眼外伤性白内障患者,行小切口非超声乳化白内障摘除手术,术中联合前房内注入TA,以帮助辨识是否有玻璃体脱出以及玻璃体所在位置.13例13眼被证实后囊膜完整,无玻璃体脱入前房患者,行小切口非超声乳化白内障摘除手术.18例18眼被证实伴有后囊膜破裂,玻璃体脱出患者行小切口非超声乳化白内障摘除联合前部玻璃体切除手术.术后随访6~12 mo.结果:所有病例均顺利完成手术.Ⅱ期角膜穿通伤患者均顺利植入人工晶状体.18例前房内注入TA证实伴有后囊膜破裂、玻璃体脱出者,在TA辅助下,明显改善了术中玻璃体皮质的辨识度,均彻底切除了前房的玻璃体.术后随访28例患者术后最佳矫正视力大于4.5.所有患者术后眼内炎症反应轻微,均未出现持续1 wk以上的高眼压及角膜水肿,人工晶状体位置居中,瞳孔位置居中.结论:曲安奈德前房内注射使得外伤性白内障手术更安全,术中后囊破裂及玻璃体脱出的处理更容易,同时可以抑制术后炎症反应.